DMD Large equally mixed donor pool

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kajita, J.
Right arrow Articles by Kobayashi, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kajita, J.
Right arrow Articles by Kobayashi, S.

Vol. 28, Issue 9, 1121-1127, September 2000

CYP3A4 Is Mainly Responsibile for the Metabolism of a New Vinca Alkaloid, Vinorelbine, in Human Liver Microsomes

Jiro Kajita, Takashi Kuwabara, Hiroyuki Kobayashi, and Satoshi Kobayashi

Drug Development Research Laboratories, Pharmaceutical Research Institute, Kyowa Hakko Kogyo Co., Ltd., Shimotogari, Nagaizumi-Cho, Sunto-Gun, Shizuoka, Japan

The metabolism of vinorelbine, a new anticancer agent belonging to the vinca alkaloid family, was investigated in human liver microsomes. Vinorelbine biotransformation consisted of one saturable and one nonsaturable process, and the Km and Vmax values for the saturable process were 1.90 µM and 25.3 pmol/min/mg of protein, respectively. Several studies, including metabolism by cytochrome P450 (CYP) enzymes in a cDNA expression system and inhibition by specific antibodies and chemical inhibitors, showed that the main CYP enzyme involved in vinorelbine metabolism was CYP3A4. Also, the effects of vinorelbine on each of the CYP activities in human liver microsomes were investigated. High concentrations (100 µM) of vinorelbine inhibited CYP3A4 activity (testosterone 6beta -hydroxylation activity) by 45.2%. However, the inhibitory effects of vinorelbine on the other CYP activities were minimal. The 50% inhibitory concentration (IC50) of vinorelbine for testosterone 6beta -hydroxylase was estimated to be 155 µM. The plasma concentration in patients is expected to be much lower than this value. These results indicate that vinorelbine metabolism is expected to be modulated by the drugs that are able to inhibit or induce CYP3A activity.

Copyright © 2000 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 The Annals of PharmacotherapyHome page
R. Yano, D. Tani, K. Watanabe, H. Tsukamoto, T. Igarashi, T. Nakamura, and M. Masada
Evaluation of Potential Interaction Between Vinorelbine and Clarithromycin
Ann. Pharmacother., March 1, 2009; 43(3): 453 - 458.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S.-H. Tan, S.-C. Lee, B.-C. Goh, and J. Wong
Pharmacogenetics in Breast Cancer Therapy
Clin. Cancer Res., December 15, 2008; 14(24): 8027 - 8041.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
D. Leveque and F. Jehl
Molecular Pharmacokinetics of Catharanthus (Vinca) Alkaloids
J. Clin. Pharmacol., May 1, 2007; 47(5): 579 - 588.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Wong, R. L. Balleine, E. Y.L. Blair, A. J. McLachlan, S. P. Ackland, M. B. Garg, S. Evans, D. Farlow, M. Collins, L. P. Rivory, et al.
Predictors of Vinorelbine Pharmacokinetics and Pharmacodynamics in Patients With Cancer
J. Clin. Oncol., June 1, 2006; 24(16): 2448 - 2455.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
J.-D. Marechal, J. Yu, S. Brown, I. Kapelioukh, E. M. Rankin, C. R. Wolf, G. C. K. Roberts, Mark. J. I. Paine, and M. J. Sutcliffe
IN SILICO AND IN VITRO SCREENING FOR INHIBITION OF CYTOCHROME P450 CYP3A4 BY COMEDICATIONS COMMONLY USED BY PATIENTS WITH CANCER
Drug Metab. Dispos., April 1, 2006; 34(4): 534 - 538.
[Abstract] [Full Text] [PDF]

Home page
 J AndrolHome page
R. Obligacion, M. Murray, and I. Ramzan
Drug-Metabolizing Enzymes and Transporters: Expression in the Human Prostate and Roles in Prostate Drug Disposition
J Androl, March 1, 2006; 27(2): 138 - 150.
[Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. C. E. McFadyen, W. T. Melvin, and G. I. Murray
Cytochrome P450 enzymes: Novel options for cancer therapeutics
Mol. Cancer Ther., March 1, 2004; 3(3): 363 - 371.
[Abstract] [Full Text]

Home page
 Drug Metab. Dispos.Home page
J. Kajita, K. Inano, E. Fuse, T. Kuwabara, and H. Kobayashi
Effects of Olopatadine, a New Antiallergic Agent, on Human Liver Microsomal Cytochrome P450 Activities
Drug Metab. Dispos., December 1, 2002; 30(12): 1504 - 1511.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
F. M. Uckun, J. Thoen, H. Chen, E. Sudbeck, C. Mao, R. Malaviya, X.-P. Liu, and C.-L. Chen
CYP1A-Mediated Metabolism of the Janus Kinase-3 Inhibitor 4-(4'-Hydroxyphenyl)-amino-6,7-dimethoxyquinazoline: Structural Basis for Inactivation by Regioselective O-Demethylation
Drug Metab. Dispos., January 1, 2002; 30(1): 74 - 85.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
K. Hotta, I. Sekine, T. Tamura, M. Sawada, H. Watanabe, H. Kusaba, Y. Akiyama, A. Inoue, T. Shimoyama, H. Nokihara, et al.
A Phase I/II Study of Cisplatin and Vinorelbine Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer
Jpn. J. Clin. Oncol., December 1, 2001; 31(12): 596 - 600.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2000 by the American Society for Pharmacology and Experimental Therapeutics.